Phaseline

Companies › ALX Oncology

ALX Oncology: clinical trials, targets and expected readouts

2 active drug programs in 9 registered trials: 6 Phase 2, 3 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Evorpacept (ALX148)
Leukocyte surface antigen CD47 inhibitor
CD47Phase 2Gastric Cancer; Head and Neck Cancer; Breast Cancer, Metastatic; Ovarian Cancer …Dec 2027
ALX2004
anti-EGFR antibody-drug conjugate
EGFRPhase 1NSCLC (Advanced Non-small Cell Lung Cancer)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05002127Evorpacept (ALX148)Phase 2Gastric CancerOncologyMay 2024
NCT04675333Evorpacept (ALX148)Phase 2Head and Neck CancerOncologyMar 2025
NCT04675294Evorpacept (ALX148)Phase 2Head and Neck CancerOncologyMar 2025
NCT07085091ALX2004Phase 1NSCLC (Advanced Non-small Cell Lung Cancer)OncologyJun 2027
NCT07007559Evorpacept (ALX148)Phase 2Breast Cancer, MetastaticOncologyDec 2027
NCT05025800Evorpacept (ALX148)Phase 1Aggressive B-Cell Non-Hodgkin LymphomaOncologyMar 2028
NCT05467670Evorpacept (ALX148)Phase 2Ovarian CancerOncologyApr 2029
NCT05787639Evorpacept (ALX148)Phase 2Oropharynx CancerOncologyOct 2029
NCT05868226Evorpacept (ALX148)Phase 1HER2-positive Breast CancerOncologyDec 2030

From the company's SEC filings

Cash and short-term investments of $138m on 2026-06-30; operating cash outflow about $70m a year; runway about 24 months at that burn, to Jun 2028; 1 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

EGFR (1) CD47 (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

ArriVent BioPharma Eikon Therapeutics Kura Oncology Lyell Immunopharma Black Diamond Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.